Want to see SE:BRAIN full AI Analyst Report?
Top Page
BrainCool AB
(BRAIN)
Select Model
Select Model
Rating:46Neutral
Price Target:
kr0.69
▼(-6.03% Downside)
Action:Reiterated
Date:08/17/26
The score is held back primarily by persistent losses and significant ongoing cash burn despite improving revenue growth. Technicals also lean bearish with the stock below key moving averages and negative MACD. A debt-free balance sheet provides some support, but valuation remains difficult to justify while earnings are negative.
Positive Factors
Improving Revenue Growth
The return to double-digit trailing revenue growth indicates improving commercial traction for BrainCool’s hospital-focused products. Sustained adoption could provide a stronger base for operating leverage, although profitability still needs to catch up.
Negative Factors
Persistent Unprofitability
Negative gross profit and deeply negative EBIT and EBITDA margins show that revenue growth has not yet produced a viable operating model. Continued losses may constrain investment capacity and increase the risk of future equity dilution.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Revenue Growth
The return to double-digit trailing revenue growth indicates improving commercial traction for BrainCool’s hospital-focused products. Sustained adoption could provide a stronger base for operating leverage, although profitability still needs to catch up.
Read all positive factors
BrainCool AB (BRAIN) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr276.41M
Dividend YieldN/A
Average Volume (3M)201.46K
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue Growth6.49%
EPS Growth25.03%
CountrySE
Employees15
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.12
Shares Outstanding394,878,140
10 Day Avg. Volume223,544
30 Day Avg. Volume201,464
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)0.85
Price to Sales (P/S)4.14
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.08
Revenue Forecast (FY)kr41.00M
BrainCool AB Business Overview & Revenue Model
Company Description
BrainCool AB (publ), a medical technology company founded in 2010 and headquartered in Lund, Sweden, focuses on the development, commercialization, and distribution of advanced medical cooling systems. Operating with its subsidiaries, the company ...
How the Company Makes Money
null...
BrainCool AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.63M | 36.21M | 39.96M | 23.23M | 17.59M | 9.26M |
| Gross Profit | -26.99M | -40.88M | 13.13M | 12.12M | -46.16M | -48.93M |
| EBITDA | -28.28M | -29.99M | -34.06M | -49.86M | -35.07M | -32.16M |
| Net Income | -34.43M | -37.05M | -44.04M | -61.28M | -45.61M | -38.75M |
Balance Sheet | ||||||
| Total Assets | 170.11M | 192.38M | 162.04M | 133.28M | 133.67M | 99.35M |
| Cash, Cash Equivalents and Short-Term Investments | 43.09M | 39.57M | 31.40M | 25.06M | 41.21M | 13.58M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 35.00M |
| Total Liabilities | 11.02M | 16.58M | 16.11M | 21.54M | 17.44M | 54.12M |
| Stockholders Equity | 159.10M | 175.80M | 145.93M | 111.74M | 116.23M | 45.23M |
Cash Flow | ||||||
| Free Cash Flow | -49.58M | -56.49M | -70.20M | -67.23M | -53.67M | -35.06M |
| Operating Cash Flow | -49.66M | -52.68M | -62.64M | -61.16M | -46.27M | -24.25M |
| Investing Cash Flow | -2.65M | -6.54M | -7.57M | -6.17M | -7.59M | -10.82M |
| Financing Cash Flow | 85.86M | 67.33M | 76.80M | 50.93M | 81.28M | 36.39M |
BrainCool AB Technical Analysis
Negative
0.73
Price Trends
0.75
Negative
0.75
Negative
0.65
Positive
Market Momentum
-0.01
Positive
41.11
Neutral
14.29
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BRAIN, the sentiment is Negative. The current price of 0.73 is above the 20-day moving average (MA) of 0.73, below the 50-day MA of 0.75, and above the 200-day MA of 0.65, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 41.11 is Neutral, neither overbought nor oversold. The STOCH value of 14.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BRAIN.
BrainCool AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | kr1.22B | 24.37 | 14.08% | 0.26% | -0.27% | 93.40% | |
60 Neutral | kr386.73M | -80.27 | -3.61% | ― | 15.87% | 92.43% | |
52 Neutral | kr543.18M | -64.58 | -2.84% | ― | -13.72% | 52.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | kr276.41M | -6.02 | -25.09% | ― | 6.49% | 25.03% | |
45 Neutral | kr1.09B | -30.61 | -3.99% | ― | -0.34% | 29.54% | |
43 Neutral | kr274.65M | -7.19 | -106.02% | ― | 65.82% | 41.28% |
* Healthcare Sector Average
SE:BRAIN
BrainCool AB
0.70
-0.33
-32.17%
SE:BACTI.B
Bactiguard Holding AB
15.20
-12.40
-44.93%
SE:CRAD.B
C-Rad AB Class B
35.80
2.60
7.84%
SE:ACARIX
Acarix AB
0.24
-0.10
-28.87%
SE:SEDANA
Sedana Medical AB
10.36
-5.24
-33.59%
SE:MNTC
Mentice AB
13.80
0.00
0.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.